StreetInsider.com News Articles

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

Tue, 07 Jul 2026 07:00:00 -0400

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC^® 2026

Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference^® 2026, taking place July 12-15 in London, UK.

Across these AAIC presentations, we are showing how AC Immune’s Morphomer^®-based small molecule approach has generated differentiated therapeutic and imaging assets. Our first-in-class TDP-43 PET tracer has generated encouraging early human imaging data in FTD and ALS; our novel brain-penetrant NLRP3 inhibitor is in Phase

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

Tue, 07 Jul 2026 07:00:00 -0400

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC^® 2026

H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)

Wed, 01 Jul 2026 07:04:43 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ: ACIU).

The analyst commented: "Yesterday, AC Immune reported interim 12-month data from the first three ABATE cohorts (AD1, AD2, AD3; n=74 prodromal AD patients). Key takeaways from the readout are as follows. First, ACI-24 was generally safe and well tolerated with no ARIA-E across any dose cohort. Second, anti-Abeta antibody responses were detected at every dose level with a dose-response relationship confirmed meaning that the immunotherapy engages the immune system as designed across the tested range. Third, AD4 is now testing ACI-24 with

Form 6-K AC Immune SA For: Jun 30

Tue, 30 Jun 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260630/26710764.html

Form 6-K AC Immune SA For: Jun 30

Tue, 30 Jun 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260630/26710764.html

AC Immune reports 12-month interim data from ACI-24 Alzheimer's trial

Tue, 30 Jun 2026 07:00:13 -0400

AC Immune SA (NASDAQ: ACIU) announced interim 12-month data from the first three cohorts of its Phase 1b/2 ABATE trial, evaluating ACI-24, an anti-amyloid beta active immunotherapy, in 74 patients with prodromal Alzheimer's disease.

According to the company's statement, ACI-24 was generally safe and well tolerated across the three cohorts, with no evidence of amyloid-related imaging abnormalities-edema (ARIA-E). Anti-amyloid beta antibody responses were detected at all dose levels, with a dose-response relationship observed.

A fourth cohort, AD4, has been initiated to test ACI-24 with an additional adjuvant intended to enhance immunogenicity. Martin Zügel, interim CEO of AC Immune and Chair of the

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

Tue, 30 Jun 2026 07:00:00 -0400

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer’s disease (AD) cohorts in ABATE
Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3
Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses

Lausanne, Switzerland, June 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

Tue, 30 Jun 2026 07:00:00 -0400

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer’s disease (AD) cohorts in ABATE
Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3
Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses

Form 4 AC Immune SA For: Jun 11 Filed by: Twyman Roy Ervin

Mon, 15 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26644154.html

Form 4 AC Immune SA For: Jun 11 Filed by: Twyman Roy Ervin

Mon, 15 Jun 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26644154.html

Form 4 AC Immune SA For: Jun 11 Filed by: AGUIAR-LUCANDER RENEE

Mon, 15 Jun 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260615/26644007.html

Form 4 AC Immune SA For: Jun 11 Filed by: AGUIAR-LUCANDER RENEE

Mon, 15 Jun 2026 06:59:00 -0400

si-local-file:///var/storage/secattach/20260615/26644007.html

Form 4 AC Immune SA For: Jun 11 Filed by: Zuegel Martin

Mon, 15 Jun 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26643983.html

Form 4 AC Immune SA For: Jun 11 Filed by: Zuegel Martin

Mon, 15 Jun 2026 06:50:00 -0400

si-local-file:///var/storage/secattach/20260615/26643983.html

Form 4 AC Immune SA For: Jun 11 Filed by: Buetler Monika

Mon, 15 Jun 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260615/26643939.html

Form 4 AC Immune SA For: Jun 11 Filed by: Buetler Monika

Mon, 15 Jun 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260615/26643939.html

Form 4 AC Immune SA For: Jun 11 Filed by: June Carl Howard

Mon, 15 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26643904.html

Form 4 AC Immune SA For: Jun 11 Filed by: June Carl Howard

Mon, 15 Jun 2026 06:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26643904.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260611/26636557.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260611/26636557.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260611/26632570.html

Form 6-K AC Immune SA For: Jun 11

Thu, 11 Jun 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260611/26632570.html

AC Immune receives $4 million grant for Parkinson's drug trial extension

Thu, 11 Jun 2026 07:00:52 -0400

AC Immune SA (NASDAQ: ACIU) announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to support extending Part 1 of its ongoing Phase 2 VacSYn trial of ACI-7104 in early Parkinson's disease.

The grant will fund a two-year extension of Part 1 of the trial, which is testing the company's anti-alpha-synuclein active immunotherapy. Final data from Part 1 of the VacSYn trial is expected in the second half of 2026.

The Vijay and Marie Goradia Charitable Foundation was established by Houston businessman and philanthropist Vijay Goradia and his wife Marie to support health, education,

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Thu, 11 Jun 2026 07:00:00 -0400

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104
Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years
Final data from Part 1 of VacSYn trial expected in H2 2026

Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Thu, 11 Jun 2026 07:00:00 -0400

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104
Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years
Final data from Part 1 of VacSYn trial expected in H2 2026